EYE nationalvision.com: Price-to-Projected Revenue Ratio

Brandmark of America's Best Contacts & Eyeglasses (EYE)

The difficulty of expanding the physical network due to personnel and rental costs is putting pressure on National Vision Holdings (EYE) quotes. The forward P/S valuation demonstrates price dynamics where 0.50 serves as the base parameter value. The company's fundamentals have been weakened by online competition and the loss of major contracts, however, the current operational pivot through the development of proprietary clinics and digitalization should stabilize the business model.

National Vision - EYE Forward P/S Multiple (period 07/04/2022 - 11/17/2026)

Comprehensive metric breakdowns and analytics for National Vision (EYE)

- market price and analyst price targets:
- company stock capitalization data:
Manufactured products of nationalvision.com

The integration of optometry and in-house lens production at National Vision Holdings (EYE) creates significant business value, which is reflected in the forward P/S ratio of 0.50. This indicator compares market capitalization with expected revenue, allowing investors to assess whether the asset is overbought or if there is potential for price growth provided the current pace of ecosystem expansion continues.

Analysis of competing companies

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|Market Cap to Expected Sales Ratio Progyny Inc (PGNY)|Ardent Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Select Medical Corp SEM|ASTH: Forward P/S Multiple|Market Cap to Projected Revenue MD|USPH (US Physical Therapy Inc) - Forward P/S Multiple|PNTG: Forward Price to Sales|Price-to-Projected Revenue Ratio Organogenesis Corp (ORGO)|NUTX (Nutex Health Corp) - Forward Price to Sales|Forward P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Market Cap to Future Revenue Ratio|EOLS - Price-to-Projected Revenue Ratio|Forward Price to Sales CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue MDWD|Price-to-Projected Revenue Ratio biote Corp.|Market Cap to Future Revenue Ratio thejoint.com JYNT|Forward P/S Multiple DCGO|Forward Price-to-Revenue Multiple P3 Health PIII|Forward P/S Multiple GANX (Gain Therapeutics Inc.)|Forward P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - Forward P/S Multiple|CLGN: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd. (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Concord Medical|AMS (American Shared Hospital Services Inc) - Forward P/S Multiple|MEDIROM Corp (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)